New report from Colliers highlights strong talent and funding ecosystem, but rising vacancies and slower leasing are reshaping the market.
BOSTON — Despite recent industry headwinds and rising lab vacancies, the Boston region continues to rank among the world’s leading life sciences hubs, supported by a deep talent pool, strong research funding, and a robust innovation ecosystem, according to a new market report from Colliers.
The report notes that the region currently supports a life sciences workforce of more than 57,000 professionals and benefits from substantial research and investment funding, including $3.4 billion in National Institutes of Health (NIH) grants and $8.1 billion in venture capital investment.
Over the past five years, the Boston market has expanded its life sciences real estate footprint by approximately 6 million square feet, or about 20 percent, underscoring the region’s long-term growth as a biotechnology and pharmaceutical powerhouse.
However, the rapid pace of construction during the previous boom has led to a significant increase in available laboratory and research space.
Vacancy Rates Rise as New Supply Outpaces Demand
Since 2019, more than 26 million square feet of life sciences space has been delivered across the Boston area. That wave of development has pushed availability to roughly 16 million square feet of direct space and 3.7 million square feet of sublease space, representing more than one-third of the market’s inventory.
The increase in supply has created favorable conditions for tenants, who now have more leasing options and greater negotiating power. At the same time, the higher vacancy levels are placing downward pressure on asking rents across the region.
Boston is now among several major U.S. life sciences markets where vacancy rates exceed 20 percent, reflecting a broader slowdown in leasing activity tied to macroeconomic conditions.
According to the Colliers report, the life sciences sector faced several challenges in 2025, including weaker public market valuations, fewer initial public offerings, and slower venture capital activity. Data from PitchBook shows that 2025 was tied for the second-fewest U.S. life sciences IPOs in the past 35 years, while venture capital investment totaled more than $33 billion, about 25 percent below the 2020–2022 average.
These financial pressures have forced some biotechnology companies to reduce headcounts, delay expansion plans, or scale back leasing activity, contributing to negative net absorption across major life sciences markets for the second consecutive year.
Boston Still Attracting Major Industry Deals
Despite the softer leasing environment, Boston continues to attract major commitments from leading biotechnology and pharmaceutical companies.
Recent transactions highlighted in the report include **Biogen’s planned 580,000-square-foot headquarters in Kendall Square, a 244,000-square-foot lease by Lila Sciences near Alewife Station, and a **75,000-square-foot deal by Eli Lilly in the Seaport District.
These deals underscore the region’s enduring appeal for life sciences companies seeking access to top-tier research universities, venture capital networks, and highly specialized talent.
Boston remains one of the top four life sciences clusters in the United States, alongside the San Francisco Bay Area, San Diego, and Philadelphia, which together accounted for more than 75 percent of all new laboratory space delivered nationally over the past five years.
Development Slows as Market Rebalances
The rapid expansion of lab space construction that defined the previous market cycle is now slowing significantly.
Nationwide, more than 50 million square feet of life sciences space was completed across major markets during the past five years, representing a 30 percent increase in inventory. But rising vacancies, higher interest rates, and tighter lending standards have caused many developers to pause or shelve new projects.
Entering 2026, only about seven million square feet of life sciences space remains under construction nationwide, much of it tied to build-to-suit projects or developments with significant preleasing commitments.
In some cases, developers have begun selling sites previously planned for laboratory construction or redesigning projects for other property types.
Signs of Stabilization Emerging
Despite the current slowdown, the report suggests that conditions in the life sciences sector may be beginning to stabilize.
Public biotechnology company valuations have rebounded and are now about 26 percent below peak levels, a significant improvement from the 60 percent decline recorded in April 2025. If that trend continues, analysts say it could help revive IPO activity and venture capital funding, giving companies the financial resources needed to expand operations and lease new space.
Other emerging drivers—including onshoring of pharmaceutical manufacturing, supply chain resilience initiatives, and the rapid growth of blockbuster drugs such as GLP-1 therapies—could also increase demand for specialized research and manufacturing facilities.
In addition, the expanding use of artificial intelligence in scientific research and drug discovery could generate new demand for advanced laboratory and technology-enabled research environments.
While the life sciences real estate market is currently adjusting to a surge in supply and a temporary slowdown in demand, Boston’s research institutions, venture capital ecosystem, and highly educated workforce continue to position the region as one of the world’s premier innovation hubs.
As construction slows and market conditions gradually rebalance, analysts expect Boston to remain a central hub for biotechnology discovery, pharmaceutical innovation, and scientific entrepreneurship in the years ahead.
